Online inquiry

IVTScrip™ mRNA-Anti-CTGF, FG-3019(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ7142MR)

This product GTTS-WQ7142MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets CTGF gene. The antibody can be applied in Hepatic fibrosis research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001901.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1490
UniProt ID P29279
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CTGF, FG-3019(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ7142MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ8264MR IVTScrip™ mRNA-Anti-PDCD1, HLX10(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA HLX10
GTTS-WQ14163MR IVTScrip™ mRNA-Anti-IL6R, aIL6R88(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA aIL6R88
GTTS-WQ2414MR IVTScrip™ mRNA-Anti-PCSK9, AMG 145(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AMG 145
GTTS-WQ6506MR IVTScrip™ mRNA-Anti-CD274, CX-072(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA CX-072
GTTS-WQ7354MR IVTScrip™ mRNA-Anti-VTCN1, FPA-150(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA FPA-150
GTTS-WQ14140MR IVTScrip™ mRNA-Anti-PCSK9, aPCSK927(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA aPCSK927
GTTS-WQ13987MR IVTScrip™ mRNA-Anti-GP, REGN-3470-3471-3479(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA REGN-3470-3471-3479
GTTS-WQ13445MR IVTScrip™ mRNA-Anti-TNFRSF10B, PRO95780(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA PRO95780
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW